ERAS - Company ID 0001761918
Erasca, Inc. trades as ERAS and has a market capitalization of $6.06 B, making it the #1282 largest US-listed company by market value. This page tracks Erasca, Inc. through 326 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
Erasca to Present at the Jefferies Global Healthcare Conference
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab
Erasca to Present at the Bank of America Securities Health Care Conference
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE
Conference call and live webcast today at 4:30 PM Eastern Time
The largest companies sharing Erasca, Inc.'s SEC industry classification (pharmaceutical preparations).
Erasca, Inc. (ERAS) has a market capitalization of $6.06 B as of 2026-07-09, ranking #1282 among US-listed companies.
In its latest fiscal year Erasca, Inc. reported a net loss of $124.55M.